Business Context and Reporting Period
Company: BiomX Inc. (PHGE)
Filing Type: Form 8-K (Current Report)
Date: May 5, 2026
BiomX Inc. has executed a fundamental strategic pivot, transitioning from a clinical-stage biopharmaceutical company to a defense, security, and critical infrastructure technology holding company. This transformation follows the discontinuation of its legacy phage therapy programs and the insolvency of its former Israeli operating subsidiary, BiomX Ltd., in December 2025. The Company has replaced its entire management team and Board of Directors, appointing Michael Oster as CEO and David Rokach as CFO. Current operations are conducted through three principal subsidiaries: DR. Frucht Systems Ltd. (DFSL), Zorro Net Ltd. (Zorronet), and X Security & Defense LTD.
Key Financial Metrics and Liquidity
Note: As this is a Current Report on Form 8-K describing a strategic transformation, it does not contain audited financial statements, revenue figures, or profit margins for the current period. Specific financial data is limited to the following:
- Revenue: The filing states the Company has "limited ongoing operations and no significant sources of revenue" outside of its new acquisitions. Zorronet projects 2026 revenues of approximately NIS 6.3 million (comprising NIS 1.2M SaaS, NIS 2M co-development, and NIS 3.1M project-based), but these are forward-looking estimates.
- Cash Flow & Liquidity: The Company has committed over $3 million in internal funds to finance X Security & Defense's 2026 operations. The filing notes a need to raise additional capital to support the new strategy.
- Debt & Obligations:
- DFSL Acquisition: Issued a $3,000,000 unsecured convertible promissory note, pre-funded warrants for 923,000 shares, and a five-year warrant for 3,692,000 shares.
- Zorronet Earnout: Assumed a performance-based earnout obligation due by March 31, 2027, equal to the greater of 125% of Zorronet's 2026 consolidated revenue or 8x its 2026 consolidated EBITDA.
- Lease Settlement: Paid a one-time settlement of $800,000 to terminate the lease for its former subsidiary, Adaptive Phage Therapeutics, LLC.
- Listing Status: Received a notice from NYSE American on March 25, 2026, regarding non-compliance with stockholders' equity listing standards. A compliance plan was submitted with a deadline of September 25, 2027.
Material Changes Versus Prior Period
- Cessation of Legacy Business: Discontinued development of lead phage product BX004 and ceased all clinical trials. The former Israeli subsidiary, BiomX Ltd., filed for insolvency in December 2025 and is no longer controlled by the Company.
- Management Overhaul: Complete transition of the Board of Directors and executive management team in Q1 2026.
- Acquisitions:
- Acquired a 60% controlling interest in DFSL, an Israeli LADAR-based detection systems company.
- Acquired 100% of Zorronet, an Israeli AI-powered security and command-and-control platform company.
- New Subsidiary: Established X Security & Defense LTD., focused on first-response technologies, including aerial firefighting systems.
Guidance, Outlook, and Risks
Outlook and Strategy: The Company intends to build a diversified portfolio in defense and security markets, targeting Counter-UAS, AI-powered command-and-control, perimeter security, and first-response technologies. Revenue is expected to be driven by project-based engagements, recurring SaaS fees from Zorronet, and co-development contracts with prime defense contractors (e.g., Elbit Systems, Rafael Advanced Defense Systems).
Material Risks:
- Regulatory Approvals: The DFSL acquisition requires approval from the Israel Innovation Authority (IIA), which may impose conditions on technology transfer or require grant repayments.
- Geopolitical Instability: Operations are concentrated in Israel. The ongoing "Swords of Iron" conflict poses risks of personnel shortages due to mandatory military reserve duty, supply chain disruptions, and potential physical damage to facilities. The Company carries no war risk insurance.
- Customer Concentration: Near-term revenue is heavily dependent on a limited number of key customers, including Elbit Systems and Rafael Advanced Defense Systems.
- Delisting Risk: Failure to regain compliance with NYSE American equity standards by September 2027 could result in delisting, impairing liquidity and potentially triggering defaults on convertible notes.
- Integration and Execution: The new management team has limited experience in the defense sector, and the Company has limited operating history in its new markets.
Investor Verification Checklist
- Verify the status of the Israel Innovation Authority (IIA) approval for the DFSL acquisition and any associated financial conditions.
- Confirm the Company's progress on its NYSE American compliance plan to avoid delisting.
- Assess the impact of mandatory Israeli military reserve duty on the workforce of DFSL and Zorronet.
- Review the specific terms of the Zorronet earnout obligation and the potential cash outflow required by March 2027.
- Monitor the Company's ability to secure stockholder approval for the issuance of shares related to the DFSL acquisition (convertible notes and warrants).
- Evaluate the Company's cash runway given the commitment of over $3 million to X Security & Defense and the lack of significant current revenue.